Written Authority Required Drugs

Drug, program or condition

Find a subsidy by drug, program or condition

In this section

Acromegaly

The PBS subsidises pasireotide and pegvisomant for patients with acromegaly.

Alzheimer's disease

The PBS subsidises medicines for eligible patients with Alzheimer's disease.

Ankylosing spondylitis

The Pharmaceutical Benefits Scheme (PBS) subsidises biological agents for patients with ankylosing spondylitis.

Arthritis - juvenile idiopathic arthritis

The PBS subsidises biological disease-modifying antirheumatic drugs for patients with severe active juvenile idiopathic arthritis.

Arthritis - psoriatic arthritis

The Pharmaceutical Benefits Scheme (PBS) subsidises biological agents for patients with severe active psoriatic arthritis.

Arthritis - rheumatoid arthritis

The Pharmaceutical Benefits Scheme (PBS) subsidises biological agents for patients with severe active rheumatoid arthritis.

Arthritis - systemic juvenile idiopathic arthritis

The PBS subsidises tocilizumab for patients with systemic juvenile idiopathic arthritis.

Asthma - severe allergic asthma - adolescent and adult patients

The PBS subsidises omalizumab for patients aged 12 years or older with uncontrolled severe allergic asthma.

Asthma - severe allergic asthma - paediatric patient

The PBS subsidises omalizumab for paediatric patients with uncontrolled severe allergic asthma.

Asthma – severe eosinophilic asthma

The Pharmaceutical Benefits Scheme (PBS) subsidises benralizumab or mepolizumab for patients with uncontrolled severe eosinophilic asthma.

Atypical haemolytic uraemic syndrome

The PBS subsidises eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS).

Autosomal dominant polycystic kidney disease

The Pharmaceutical Benefits Scheme (PBS) subsidises tolvaptan for patients with autosomal dominant polycystic kidney disease (ADPKD).

Basal cell carcinoma - metastatic or locally advanced

The PBS subsidises sonidegib and vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

Breast cancer - locally advanced HER2 positive breast cancer

The PBS subsidises trastuzumab for patients with human epidermal growth factor receptor 2 (HER2) positive locally advanced breast cancer.

Breast cancer - metastatic breast cancer

The PBS subsidises lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine for patients with metastatic breast cancer.

BH4 deficiency

The PBS subsidises sapropterin for patients with tetrahydrobiopterin (BH4) deficiency.

Crohn's disease - adult patient

The PBS subsidises biological agents for adult patients with severe Crohn's disease.

Crohn's disease - fistulising Crohn's disease

The PBS subsidises biological agents for patients with complex refractory fistulising Crohn's disease.

Crohn's disease - paediatric patient

The PBS subsidises biological agents for paediatric patients with severe refractory Crohn's disease.

Cystic fibrosis

The PBS subsidises ivacaftor and lumacaftor+ivacaftor for patients with cystic fibrosis.

Eye - diabetic macular oedema

The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).

Eye - retinal vein occlusion

The PBS subsidises aflibercept, dexamethasone, intravitreal implant and ranibizumab for patients with branched or central retinal vein occlusion with macular oedema.

Eye - subfoveal choroidal neovascularisation

The PBS subsidises aflibercept, ranibizumab and verteporfin for patients with subfoveal choroidal neovascularisation.

Gastric cancer - metastatic (stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction

The PBS subsidises trastuzumab for patients with metastatic (stage IV) HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.

Gastrointestinal stromal tumour (GIST) - adjuvant

The PBS subsidises imatinib mesilate for patients with resected primary gastrointestinal stromal tumour (GIST) with high risk of recurrence.

Gastrointestinal stromal tumour (GIST) - metastatic or unresectable

The PBS subsidises imatinib mesilate for patients with metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).

Gastrointestinal stromal tumour (GIST) - sunitinib malate

The PBS subsidises sunitinib malate for patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).

Granulomatosis - severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis

The PBS subsidises rituximab for patients with severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis.

Growth hormone deficiency - adult patients

The Pharmaceutical Benefits Scheme (PBS) subsidises somatropin for adult patients with severe growth hormone deficiency.

Growth Hormone Program - paediatric patients

The Growth Hormone Program provides subsidised PBS treatment to eligible paediatric patients under a number of categories.

Hidradenitis Suppurativa

The PBS subsidises adalimumab for patients with moderate to severe hidradenitis suppurativa (HS).

Hypercholesterolaemia

The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia or familial heterozygous hypercholesterolaemia.

Idiopathic pulmonary fibrosis

The PBS subsidises nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis (IPF).

Idiopathic thrombocytopenic purpura

The PBS subsidises eltrombopag and romiplostim for patients with severe chronic immune idiopathic thrombocytopenic purpura.

Leukaemia - acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib and ponatinib for patients with acute lymphoblastic leukaemia (ALL).

Leukaemia - acute myeloid leukaemia

The Pharmaceutical Benefits Scheme (PBS) subsidises midostaurin for patients with acute myeloid leukaemia.

Leukaemia - chronic lymphocytic leukaemia

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with chronic lymphocytic leukaemia.

Leukaemia - chronic myeloid leukaemia

The PBS subsidises tyrosine kinase inhibitor (TKI) agents for patients with chronic myeloid leukaemia (CML).

Lymphoma - cutaneous T-cell lymphoma

The PBS subsidises vorinostat for patients with cutaneous T-cell lymphoma (CTCL).

Lymphoma - Hodgkin lymphoma

The PBS subsidises brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma.

Lymphoma - refractory follicular B-cell non-Hodgkin’s lymphoma

The PBS subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

Lymphoma - small lymphocytic lymphoma

The PBS subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).

Lymphoma - systemic anaplastic large cell lymphoma

The PBS subsidises brentuximab vedotin for eligible patients with systemic anaplastic large cell lymphoma.

Multiple myeloma

The PBS subsidises lenalidomide and pomalidomide for patients with multiple myeloma.

Myelodysplastic syndrome - azacitidine

The PBS subsidises azacitidine for patients with myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia.

Myelodysplastic syndrome - lenalidomide

The PBS subsidises lenalidomide for patients with myelodysplastic syndrome classified as low risk or Intermediate-1.

Myelofibrosis

The PBS subsidises ruxolitinib for patients with myelofibrosis.

Narcolepsy

The PBS subsidises modafinil and armodafinil for patients with narcolepsy.

Non-radiographic axial spondyloarthritis

The Pharmaceutical Benefits Scheme (PBS) subsidises golimumab for patients with non-radiographic axial spondyloarthritis.

Non-small cell lung cancer

The PBS subsidises crizotinib and osimertinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Psoriasis - severe chronic plaque psoriasis - adult patients

The Pharmaceutical Benefits Scheme (PBS) subsidises biological agents for adult patients with severe chronic plaque psoriasis.

Psoriasis - severe chronic plaque psoriasis - patients under 18 years

The PBS subsidises etanercept for patients under 18 years with severe chronic plaque psoriasis.

Pulmonary hypertension - chronic thromboembolic pulmonary hypertension

The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension.

Pulmonary hypertension - arterial

The PBS subsidises a range of medicines for patients with primary pulmonary and pulmonary arterial hypertension.

Rare diseases

The PBS subsidises imatinib mesilate for patients with rare diseases.

Spinal Muscular Atrophy

The Pharmaceutical Benefits Scheme (PBS) subsidises nusinersen for patients with spinal muscular atrophy (SMA).

Ulcerative colitis

The PBS subsidises biological agents for patients with moderate to severe ulcerative colitis.

Urticaria - severe chronic spontaneous urticaria

The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.

Page last updated: 22 February 2019